Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Vanda Pharmaceuticals

Evaluate

Thumbnail
January 06, 2021

US FDA approval tracker: December 2020

Thumbnail
November 27, 2020

Go or no go? The year ends with Covid-19 vaccine approvals in sight

December promises big US decisions for Novartis, Astrazeneca and Fibrogen, as well as the FDA's first Covid-19 vaccine reviews.

Article image
Vantage logo
September 02, 2019

US FDA approvals tracker: August

Article image
Vantage logo
July 26, 2019

Go or no go? Abbvie, Roche and Kala await key decisions

One of the biggest drugs of the year, Abbvie’s Jak inhibitor upadacitinib, could get the nod in August.

Article image
Vantage logo
December 11, 2018

Vanda preps Hetlioz for a new market

The company hails a partial clinical trial win as the way in to a new use for Hetlioz, but the stock markets are less convinced.

Article image
Vantage logo
December 04, 2018

One down, one to go for Vanda’s year-end data blitz

Article image
Vantage logo
November 23, 2018

Upcoming events – Vanda Pharmaceuticals awaits two catalysts and Evofem tries again

A two-for-one holiday sale is coming for Hetlioz and tradipitant, and Evofem hopes to confirm its contraceptive gel's effectiveness.

Vantage logo
September 23, 2015

After Turing, the industry’s biggest price gougers

Vantage logo
April 10, 2015

Good times roll in Q1 as mid and small cap winners outnumber losers

Vantage logo
August 18, 2014

Leaders and laggards in FDA approval stakes

Vantage logo
November 15, 2013

Despite shock adcom vote, Vanda will struggle to remain relevant

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up